Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus
- 1 February 2018
- journal article
- review article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (4) , 509-512
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Role of ranolazine in angina, heart failure, arrhythmias, and diabetesPharmacology & Therapeutics, 2012
- Ranolazine reduces Ca2+ overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated heartsPharmacological Research, 2011
- Ranolazine Increases β-Cell Survival and Improves Glucose Homeostasis in Low-Dose Streptozotocin-Induced Diabetes in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2011
- The Effect of Oral Antidiabetic Agents on A1C LevelsDiabetes Care, 2010
- Effect of Ranolazine on A1C and Glucose Levels in Hyperglycemic Patients With Non-ST Elevation Acute Coronary SyndromeDiabetes Care, 2010
- Standards of Medical Care in Diabetes—2007Diabetes Care, 2007
- Ranolazine for the Treatment of Chronic Angina and Potential Use in Other Cardiovascular ConditionsCirculation, 2006
- Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetesEuropean Heart Journal, 2005
- Inhibition of late (sustained/ persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte functionEuropean Heart Journal Supplements, 2004
- Mortality from Coronary Heart Disease in Subjects with Type 2 Diabetes and in Nondiabetic Subjects with and without Prior Myocardial InfarctionNew England Journal of Medicine, 1998